Kirshner J, Chen CJ, Liu P, Huang J, Shively JE. CEACAM1-4S, a cell-cell adhesion molecule, mediates apoptosis and reverts mammary carcinoma cells to a normal morphogenic phenotype in a 3D culture. Proc Natl Acad Sci U S A; 2003, 100(2): 521-6.
Kirshner J, Schumann D, Shively JE. CEACAM1, a cell-cell adhesion molecule, directly associates with annexin II in a three-dimensional model of mammary morphogenesis. Journal of Biological Chemistry; 2003, 278(50): 50338-50345.
Lopatin G, Liu A, Raubitschek A, Williams LE. Software architecture for real time radionuclide dosimetry. Medical Physics; 2003, 30(6): 1400.
Pavlinkova G, Batra SK, Colcher D, Booth BJ, Baranowska KJ. Constructs of biotin mimetic peptide with CC49 single-chain Fv designed for tumor pretargeting. Peptides; 2003, 24(3): 353-362.
Reeve JR, Keire DA, Coskun T, Green GM, Evans C, Ho FJ, Lee TD, Davis MT, Shively JE, Solomon TE. Synthesis of biologically active canine CCK-58. Regulatory Peptides; 2003, 113(1-3): 71-77.
Sun JY, Anand JV, Chatterjee S, Wong KK. Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther; 2003, 10(11): 964-76.
Sun JY, Senitzer D, Forman SJ, Chatterjee S, Wong KK. Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes. Cancer Immunology Immunotherapy; 2003, 52(12): 761-770.
Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, Williams LE, Chatziioannou AF, Gambhir SS, Wu AM. I-124-labeled engineered Anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. Journal of Nuclear Medicine; 2003, 44(12): 1962-1969.
Topp MS, Riddell SR, Akatsuka Y, Jensen MC, Blattman JN, Greenberg PD. Restoration of CD28 Expression in CD28- CD8+ Memory Effector T Cells Reconstitutes Antigen-induced IL-2 Production. J Exp Med; 2003, 198(6): 947-55.
Williams LE, Kaplan D, Wu A, Yazaki P, Shively J, Liu A, Raubitschek A, Wong JY. Pharmacokinetic modeling of cognate monoclonal antibodies (Mabs) prior to clinical imaing trials. Medical Physics; 2003, 30(6): 1458.
Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, Yazaki PJ, Shively JE, Doroshow JH, Raubitschek AA. A phase I trial of Y-90-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clinical Cancer Research; 2003, 9(16): 5842-5852.
Wong JY, Chu D, Williams LE, Yamauchi DM, Ikle D, Wilczynski S, Colcher D, Yazaki P, Shively J, Wu A, Raubitschek A. Tumor imaging with a I-123-labeled 80 kD engineered anti-CEA antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Journal of Nuclear Medicine; 2003, 44(5): 402P-402P.
Lee WH, Ramos T, Krymskaya L, Liu CP. Development of T cells expressing an altered TCR complex. European Journal of Immunology; 2003, 33(10): 2696-2705.
You S, Chen C, Lee WH, Wu CH, Judkowski V, Pinilla C, Wilson DB, Liu CP. Detection and characterization of T cells specific for BDC2.5 T cell-stimulating peptides. Journal of Immunology; 2003, 170(8): 4011-4020.
